News
Intervet sees 6% global growth
01 March 2007
THE NETHERLANDS - Revenues at Intervet increased by 3% to EUR 1,125 million boosted by strong autonomous growth of 6% across all regions and product lines. Outpacing market growth, EBIT before incidentals increased 2% to EUR 213 million, resulting in an EBIT margin of 18.9%. Divestments and acquisitions had a negative impact on revenues of 3%.
In Europe, autonomous growth was 5%, while in North America, revenues from ongoing operations grew 12%. At the end of the year, Intervet received important product approvals for Zilmax®, a feed additive for cattle and PreveNile®, a West Nile Virus vaccine for horses.
| ThePigSite News Desk | More MSD Animal Health News |
Share This
Related News
More News
Our Sponsors
Partners
© 2000 - 2012. 5m Publishing, Benchmark House, 8 Smithy Wood Drive, Sheffield, S35 1QN, England.